ANDA 87535, held by Organon USA. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 87535 (Methylprednisolone), held by Organon USA, was first approved by FDA on Jun 25, 1982, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 1982 | Original application | Approved | None posted |
| MethylprednisoloneEQ 500MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| MethylprednisoloneEQ 1GM BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Apr 12, 1985 | Supplement 3Manufacturing | Approved | None posted |
| Apr 12, 1985 | Supplement 5Manufacturing | Approved | None posted |
| Feb 28, 1983 | Supplement 1Manufacturing | Approved | None posted |
| Jun 25, 1982 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters